Long Covid: mass disability and broad societal consequences [Cause Exploration Prizes]

SiebeRozendal11 Aug 2022 13:52 UTC
39 points
31 commentsEA link

Context: I’m an EA with Long Covid and a contributor to a new research organisation aiming to solve Long Covid. Due to my limited capacity, this is in the form of bullet points.

Summary

The scale of Long Covid

  • The scale of Long Covid is large: 120 million (70% confidence interval: 60 mln. to 180 mln.) worldwide as of May 2022

  • Due to many infections and limited protection by vaccines, current growth rate appears to be ~120 million/​year

  • We should expect this rate of disability to have very significant effects on society and economies worldwide

  • There is large uncertainty around the true prevalence, thus independent research is valuable

  • Health effects after COVID even without direct symptoms (‘asymptomatic Long Covid’): brain damage, immune damage, increased mortality → Very concerning trajectory of long-term societal effects

Tractability & Crowdedness

  • Symptomatic Long Covid: strongly suggestive evidence that Long Covid is a chronic infection in many cases → can be treated with many therapeutics in development for acute COVID

  • Asymptomatic Long Covid: requires prevention

  • Quite neglected

Conclusion

  • Prevention, treatment, and further cause area research are all impactful

  • Comparable to climate change in scale and societal impact, but developing on shorter timescale, more neglected, and (symptomatic Long Covid) is more tractable to solve

Introduction

  • Focus on deaths has overshadowed disability from Long Covid

  • Many viruses/​epidemics lead to long-term disease

  • In this post, I argue that initial data is convincing enough that Long Covid warrants attention, action, and funding from neartermists

    • maybe even longtermists because of broad societal effects

  • Exploratory, not in-depth, and I don’t pretend to be objective (but I try good faith argumentation)

  • I take a cluster-argument approach: many different reasons to believe Long Covid is large and important, even though some sources will not withstand in-depth scrutiny

What is Long Covid?

  • I use the following definition: any health effects lasting longer than 3 months that were primarily caused by COVID infection

  • Health effects such as (see Wikipedia):

    • Vasculitis/​endothelial dysfunction

    • Neuroinflammation

    • Microscopic blood clots

    • Reduced oxygen extraction from blood into cells

    • Insomnia

    • GI issues/​gut dysbiosis

    • Cognitive impairment

    • Post-exertional symptom exacerbation

    • Orthostatic intolerance

    • Intolerance to stimuli (sounds, light)

  • Subset of patients have:

    • Myalgic encephalomyelitis (aka “chronic fatigue syndrome”, ME/​CFS)

    • Postural Orthostatic Tachycardia Syndrome (POTS): symptoms increase by sitting/​standing upright

  • Severity:

  • Although hospitalisation and ICU increase risk of Long Covid, most Long Covid patients had a mild or asymptomatic acute phase

  • Pace of research (incl. acute COVID and basic virology) is high, but unfocused.

The scale of Long Covid is large

Two methods to estimate total number of Long Covid cases:

  1. Sample the population

  2. Estimate and multiply parameters separately

    1. How many infections become Long Covid?

    2. How many Long Covid cases recover within 1 year?

    3. How many people have been infected?

For simplicity, I use data from Western countries and assume it roughly extrapolates worldwide, except for China[1].

Method 1: population samples

  • As of early May 2022, 2.2% of the UK population self-reports to currently suffer from ongoing symptoms for at least 12 weeks, and 1.25% for longer than a year, according to the UK’s Office of National Statistics. Of those, roughly 50% are impaired ‘a little’, and another 20% ‘a lot’.

    • Advantages of this dataset: updates monthly, population representative

    • Drawbacks: no control group, self report

    • Issues with self-report:

      • Overestimate/​over-attribution possible

      • Underestimate/​under-attribution: people may not be aware their symptoms are due to COVID (Long Covid can be caused by asymptomatic infection)

  • Mid June 2022, US CDC reports 7.5% of the US population currently has symptoms that have lasted longer than 3 months since COVID infection

    • Difference with UK ONS: US respondents are asked ‘any symptoms since COVID’ whereas ONS asks respondents whether they’d describe their symptoms as Long Covid, i.e symptoms after COVID not explained by something else

  • If we extrapolate the UK data to the world population minus China and adjust for demographics but nothing else, we arrive at ~120 million cases of Long Covid (> 12 weeks) as of May 2022. (extrapolation, explanation)

  • Unfortunately, population samples are becoming less accurate; people are testing less, thus are less likely to know they’ve had COVID for sure. Any long-term symptoms are consequently attributed less to COVID.

Method 2: assessing parameters separately

  • Many numbers for each parameter, no consensus. I don’t feel comfortable making a single guesstimate. Instead, I present a collection of numbers for each parameter

a) How many infections turn into Long Covid?

ONS self-reporting survey implies ~12% of people who have had COVID report having symptoms they would describe as ‘Long Covid’ 12 weeks after infection (no control)

  • There are many studies done on the prevalence of Long Covid, with estimates ranging widely. Many have methodological issues (no controls, sampling bias)

  • The probability of Long Covid is dynamic, changing based on e.g. amount of vaccinations, time since vaccination, antigenic difference between strains in case of multiple infections, number of reinfections

Other large scale studies (mixed rates of vaccination):[2]

  • “Malaise and fatigue” reported to be 1.3% higher 6 months after infection in ~74,000 COVID-positive veterans compared to a control group of ~5 million (USDVA[3]). In another study with a similar dataset, ‘at least one symptom’ after infection was ~5% higher than control group (USDVA)

  • Dr. Claire Stevens[4] believes the ONS data is roughly a 2x overestimate, based on the ZOE Study, which reports 2.6% of COVID-positive cases to still have symptoms more than 12 weeks after infection (source)[5]

  • In Dutch study, in the COVID-positive group (n > 4,000), people reporting at least 1 symptom was 12.7% higher (21.4% vs. 8.7%) than the control group (n > 8,000), 90-150 days after infection

  • CDC reports almost 1 in 5 (19%) will develop Long Covid after infection. No controls

Related numbers

  • 12.7% of patients with COVID-19 shed fecal viral RNA 4 months after diagnosis, 3.8% at 7 months, and 0% at 10 months. Presence of faecal SARS-CoV-2 RNA is associated with gastrointestinal symptoms

  • Between Q4-2019 and Q1-2022, the number of people aged 16-64 years that are outside the workforce and do not want a job because of (any) long-term illness has risen by 320,000 (0.8% of the 16-64 age population) and 30,000 because of short-term illness (0.07%). (Bank of England)

    • Note that this is 1-2x more than the amount of people reporting they’re “impaired a lot”[6]

UK’s disability was already rising, but has shot upward since the pandemic. The US data shows that not all labour force dropouts are captured in disability data. Presumably, this is because they are either in the acute phase, recovering, or still hoping to recover. Source: Financial Times

Long Covid risk is changing over time

  • This makes the analysis substantially more difficult

  • Ideally, one would calculate a weighted risk adjusted for the following

    • vaccines

    • reinfections

    • new strains

Vaccines

  • Vaccination doesn’t fully protect against, but reduces the risk of developing Long Covid by 15-85%

    • 15% (USDVA)

    • ~50–67% (early 2022 review study)

    • 75% (2 vaccinations) or 84% (3 vaccinations); (cohort study)

    • Personally, 50-75% reduction seems a reasonable estimate

  • Increasing vaccination rates (UK) may dampen growth of Long Covid, if boosters have good uptake

  • The higher vaccination efficacy, the less accurate is extrapolation from UK to world (underestimates Long Covid in low vaccine rate countries)

Reinfections

  • Previous infection confers little long-term protection (USDVA), and new variants probably will compete on escaping prior immunity (see antigenic sin, antigenic drift).

New strains

  • I see no theoretical reason to believe there’s lower risk, all things equal

  • I would expect variants with better immune evasion to 1) generate a milder acute phase, 2) be more likely to establish viral reservoirs

  • ONS reported lower Long Covid incidence for Omicron BA.1 and BA.2 compared to Delta (odds ratios of 0.5 and 0.6, respectively) for double vaccinated individuals. For triple vaccinated individuals, there was no difference.

Based on UK ONS data. Long Covid prevalence relative to cumulative infections has definitely dropped.

  • Unfortunately, the above graph contains a confounding factor: we should expect a cumulative rate to always grow faster (because people can count more than once) than a prevalence rate. But I was unable to access data on new Long Covid cases per month.

  • The drop in the last 3 months can be explained by reduced testing.

  • The relative prevalence cannot be directly compared to the probabilities mentioned in section a), because the blue line does not include people who developed Long Covid but have already recovered.

  • My takeaway: I think it is unlikely the rate of Long Covid will drop further over time, compared to April 2022, unless:

    • Significantly better vaccines are rolled out

    • A new variant is extraordinarily different

b) How many Long Covid patients recover within 1 year of symptom onset?

  • To predict Long Covid prevalence longer than 3 months, we need to know how many recover

  • Recovery rates after 3 months aren’t good in ONS data: −11% to +37% have recovered 9 months later

    • Yes, that’s a negative recovery rate: in some months, more people are sick for 12 months compared to sick for 3 months, 9 months earlier.[7]

  • I believe that the actual recovery rate is probably higher

  • I believe recovery after 1 year to be low (<10%/​year). I’m ignoring that for simplicity.

  • Prospective cohort study (n=968) by Tran et al. (2022) had 15% full remission between month 2 and month 12

Symptoms and disease impact over time. Decreasing prevalence for 27⁄53 symptoms, a stable prevalence for 18⁄53 symptoms, and an increasing prevalence for 8⁄53 symptoms. From Tran et al. (2022)

c) Estimating cumulative infections

  • Intuitive heuristic: average amount of infections per person

    • E.g. if it’s 0.2, you should expect to see 1 in 5 of your social network to have had 1 infection. If it’s 1.2, you should expect most people you know to have been infected, and some people more than once.

  • In the graph below, I have

    • summed the incidence rates of ONS infection survey (large scale random sampling) for England[8]

      • I adjusted the numbers for a false negative rate of 15%[9].

      • I shifted these by 3 months. Infections at x = April 2022 are from January 2022. Now, the Long Covid prevalence (which lags by 3 months) can be visually compared to infections 3 months earlier.

    • Calculated the Long Covid Prevalence for symptoms lasting at least 12 weeks

    • Calculated the Long Covid prevalence for symptoms lasting at least 1 year.

      • I shifted these by 9 months later for visual comparability. Prevalence at x = March 2021 reflect cases reported at December 2021.

    • Calculated the percentage of cases that were reported, calculated by dividing the reported cases by the estimated cases based on the Infection Survey.

      • I am assuming this correlates to some extent with at-home testing.

Based on UK ONS data

  • First things first: why did Long Covid cases flatline in the last 2 months?

    • As we can see, testing has massively decreased. People in the ONS Long Covid survey are asked about lasting symptoms from covid. Based on this data, I believe the flatlining in the last 2 months is caused by people not knowing their long-lasting symptoms are from covid.

    • Unfortunately, this means

      • We can not use the ONS data to keep track of Long Covid prevalence in the future

      • More and more people are going to have unexplained symptoms

  • Now, how many people have been infected?

    • At the start of April 2022, roughly 2.02% had Long Covid in the UK, as the result of 0.61 infections/​person. This means a 3.31% prevalence:infection rate.

    • Latest known infections are 1.47/​person (mid June). I think we’re currently (mid August) at ~1.8.

  • Note again that 3.3% is not directly comparable to the figures at a). However, it definitely seems to be in the same ballpark.

  • My conclusion: UK ONS prevalence seems reasonable median estimate, but we should have wide uncertainty interval

  • In my personal estimate, I have the UK ONS data as median, and a 70% confidence interval of 0.5x to 1.5x

We should expect many more cases

[UPDATE NOV 2022: turns out this forecast was wrong and incidence (new cases) is decreasing, severity of new cases is decreasing, and significant amounts of people are recovering in the <1 year category. I now expect prevalence to be stagnating/​decreasing for a while, and then slowly growing over the next few years.]

  • As things currently look, there will still be many (re)infections.

  • Waning vaccine immunity and limited uptake of further boosters may further dampen the protective effect of vaccines on Long Covid prevalence

  • The sheer amount of infections by omicron variants will still lead to many more cases of Long Covid.

  • The growth rate of Long Covid prevalence might decrease as most at risk patients already developed Long Covid, but I would be surprised if this has substantial effects on the growth rate

  • This will only stop if the pandemic is curbed, via either next generation vaccines that prevent infection and create herd immunity, or large uptake of therapeutics that prevent development of Long Covid (unlikely)

  • I extrapolated UK ONS numbers to world population excluding China, adjusted for demographics and nothing else (data, explanation).

  • If we ignore the invalid growth rates of the last 2 months, the average growth rate in 2022 (since Omicron BA.1) is ~10 million/​month. If that rate holds, this (simplistic) model predicts the following by the end of 2023.

Estimated global Long Covid cases with symptoms longer than 12 weeks, based on UK, until early July 2022. Forecasted until end of 2023.

  • Please note that these are not my all-things-considered predictions.

    • The confidence bars represent my 70% confidence that the UK data this is based on, falls within this interval.

    • They don’t account for a change in pandemic response, effective therapeutics, effective vaccination, or different vaccination rates worldwide.

    • However, I do think it’s a reasonable median scenario to assume

    • Vaccination rate worldwide is definitely lower than UK, so the extrapolation is more likely to be higher than the median of this extrapolation.

Effects of Long Covid on society

Note: this part is more a case for reduction/​prevention of cases, rather than for treatment of viral persistence

Health effects of ‘asymptomatic Long Covid’

  • There are concerns of long-term complications that do not initially manifest in symptoms (we can call this ‘asymptomatic Long Covid’).

  • 2.4% increased risk of death (USDVA)

  • Prior COVID infection appears to increase risk of cardiovascular events by 50-70% (USDVA), increasing even in non-risk groups

Correlation between heart disease is even visible in this mortality graph. From Health Systems Tracker
Brain damage is also showing up in population data. Via Bloomberg.

  • There are more effects, such as lowered testosterone in men. I expect we will find more long-term health effects over time, especially as infections accumulate

Economic effects

  • High rates of disability contribute to labour shortage, which has wide-ranging economic effects.

UK – Workforce (Millions of People). Bank of England.

  • People living in poverty/​hand-to-mouth will be very hard hit[11]

  • Burden on care systems (doctors & caretakers), caused by increased disease and mortality + disabled/​burned-out healthcare workers → lower quality of care → more loss of healthy life years[12]

  • This is also affecting the effective altruism labour pool

Susceptibility to pandemics (speculative)

  • Reduced immune function could lead to more susceptibility to other infectious diseases

  • This could be a contributor to the monkeypox outbreak

  • This would be a massive risk factor for biorisk, if true

Decision-making & reduced cognition

  • The fact that COVID can cause lasting brain damage and cognitive issues on a large scale should be very concerning

  • Effects are hard to quantify/​identify, but it’s a factor affecting any cause you care about

  • Examples of consequences: worse decisions by those in power, reduced impulse control, worse communication, reduced research quality

Tail risks

  • Given the high uncertainty around prevalence there’s a non-negligible probability that already a lot more than 2% of the population has Long Covid. If so, continued reinfection would lead to even larger societal disruption

  • Long-term complications from ‘asymptomatic Long Covid’ can be more severe than foreseen

Outside view

“This sounds dire, but also unprecedented. Surely we would have seen this in previous pandemics? Otherwise, what’s unique about the current pandemic?”

  • I think similar disability happened after other pandemics like the 1918 Spanish flu, but it was largely ignored

    • See e.g. the 1919 famine in Tanzania, which was caused by workers being too exhausted to work the field (+ supposedly a fraction of the working population having died)

    • Without modern communication, the current patient community would not have been able to raise the alarm

    • There seems to be a cultural phenomenon of ‘pandemic forgetting’

  • SARS-CoV-2 seems relatively effective at causing long-term disease

  • Modern interconnectedness and scale giving unprecedented rate of mutations and reinfections

Tractability

This section only relates to ‘symptomatic Long Covid’. Also: I have no biomedical background.

The Viral Persistence Hypothesis is the idea that some SARS-CoV-2 infections are not fully cleared. Instead, (small) amounts of virus may persist in patient tissue by evading the immune system. There, it can provoke ongoing inflammation, aberrant immune responses, affect host metabolism, and consequently damage the patient’s body and interfere with normal functioning. Locations of persistence are called viral reservoirs.

Occam’s Razor: viral persistence is one of the simplest explanations.

There is plenty of evidence of other RNA viruses persisting in many different ways. Traditional virology accepts that many RNA viruses can persist, also in immunocompetent humans. However, it is very understudied, especially in how it relates to particular chronic diseases. Most virologists and MDs are not aware of the latest research in this area.

Standard approaches to diagnose infection are not sufficient to exclude viral persistence:

  • Antibodies not reliable

  • PCR for viral protein in blood/​other fluids/​feces; easiest place to remove by immune system

  • Expectation: in tissue → biopsies are gold standard

Evidence is strongly suggestive of viral persistence:

Alternative hypotheses for root cause(s)

A number of disease processes have been found. In theory, these could by themselves account for ongoing symptoms. However, it seems more likely that they are downstream consequences of viral persistence.[14]

  • Autoimmunity triggered during acute infection

    • Autoimmune markers have been found (e.g. auto antibodies)

    • Fits traditional autoimmunity paradigm that immune system can be “triggered” into self-harming equilibria by viruses[15], including SARS-COV-2

    • Alternatively, autoimmunity is the side effect of the immune system targeting ongoing pathogen activity but being unable to resolve it (via e.g. ‘molecular mimicry’ or ‘bystander activation’)

  • Self-sustaining inflammatory cascade

    • Inflammation is both a repair and destroy function.

    • Could theoretically self sustain

  • Self-sustaining clotting cascade

    • Microscopic blood clots have been found in most cases

    • Could theoretically self sustain

    • More likely to be driven by spike protein

  • Reactivated pathogen(s)

    • E.g. landmark paper showed 1 in 3 patients who developed Long Covid had reactivation of Epstein-Barr Virus during the acute phase

    • Reactivated pathogens could drive disease even after SARS-COV-2 clearance

Postvax anomaly

  • Some people present with identical symptoms to Long Covid immediately after vaccination[16], and subset of these are allegedly never infected

  • Potentially conflicts with viral persistence hypothesis: if same symptoms can be caused by vaccines, viral persistence isn’t necessary

  • However, it’s hard to rule out prior infection. Perhaps there is viral persistence, and a vaccine induces a stronger (but not sufficient) immune response, leading to symptoms

  • Also possible for two different mechanisms to cause same symptoms

Viral persistence offers clear targets for symptom resolution

  • If Long Covid is often caused by viral persistence in tissues, the logical solution is to aim for viral clearance or permanent viral suppression.

  • Case studies exist of patients with Long Covid and other infection-associated chronic diseases in which all symptoms disappear after successful antiviral therapy. Nonetheless, it remains a possibility that there is organ damage irreversible by antiviral therapy.

  • Viral clearance/​suppression can be achieved with the right combination of antivirals (including monoclonal antibodies) and immonusupportive drugs.

  • Many of these drugs are already being developed, researched, and approved for acute COVID.

  • Besides discovering effective treatment, deploying accurate diagnostics and achieving worldwide accessibility to treatment will still be challenges.

Secondary effects of addressing Long Covid

Long Covid research may

  • Accelerate a paradigm shift towards the role of chronic infections in a wide range of diseases

  • Create scientific opportunities in other fields by using new methods and technologies

And it may have specific positive spillover effects on

  • Other diseases that are linked to chronic infections, such as ME/​CFS, Lyme, and MS

    • More speculatively: Parkinson’s, Alzheimer’s, and (other) autoimmune diseases

  • Pandemic response therapeutics (e.g. immunomodulating therapeutics, antiviral combinations)

  • All virally-mediated diseases

Urgency

  • Earlier treatment likely more effective

  • Earlier treatment less disruptive to lives and society than long-term illness

Crowdedness

  • Current treatments are largely ineffective or even harmful, relying often on ‘reconditiniong’

  • NIH is biggest funder ($1.15B), but not able to distribute it fast, effectively, and flexibly (see e.g. criticism in The Atlantic[17])

  • Other countries have smaller budgets, and not allocating much to promising treatments (none to antivirals)

  • Lots of research groups working on acute COVID, SARS-COV-2, and a decent amount on Long Covid with (presumably) pre-existing budgets

  • Balvi/​Vitalik Buterin: funded $6M to Patient-Led Research Collaborative + $1.4M to gut biopsy study by PolyBio/​Mt. Sinai

  • Institutional biases:

    • Acknowledging Long Covid in conflict with “let it rip” policy of many governments and current social norms

    • ME/​CFS is the most underfunded disease in relation to disease burden

    • ME/​CFS has a long history of being dismissed as ‘psychosomatic’

  • If current growth rates continue, hard to imagine governments not starting to fund significant amounts within a year or three

    • Will depend on which infrastructure exists then, whether that funding is used effectively

  • Personal impression: absent ‘intervention’, current time to a treatment with 50% efficacy (relieving 90% of a patient’s health burden) seems like >10 (70% confidence: 5-25) years.

  • The field lacks coordination, speed, and a vehicle for pharmaceutical companies to collaborate

Conclusion

  • I’m really very concerned

  • Tentatively, I want to say that symptomatic + asymptomatic Long Covid is comparable in scale/​societal disruption to climate change

    • But developing faster

    • And more tractable to solve (especially symptomatic Long Covid)

  • Next month, I will share more about the organisation I’m helping, when they launch publicly.

    • They have $50-100 million room for funding that can be rapidly deployed usefully

Policy implications

  • Often mentioned by other organisations regarding covid prevention/​mitigation:

    • healthy indoor air: HEPA, CO2 monitoring, UVC ceiling lights

    • masking indoors/​certain public spaces like hospitals, pharmacies, supermarkets

  • High value to zero COVID via next generation vaccines (e.g. nasal, T-cell) in addition to above non-pharmaceutical interventions

  • High value of information for more robust cause area research and exploratory grants

    • Including the speculative risks of cognitive decline and immune damage

  • Value in protecting the EA labour pool by increasing the air safety of physical EA spaces

  • Research into treatments is very urgent and likely very cost-effective

  • Large scale diagnosis should be urgently pursued

  • Large scale treatment will be a later bottleneck

Possible actions people can take individually

  • If any potential funders are convinced Long Covid is worth funding, you can contact me at sieberozendal@gmail.com

  • Do cause area research.[18] I’m happy to assist in the capacity of ‘expert to be consulted’ rather than ‘research mentor’

  • Figure out biggest obstacles in COVID mitigation/​prevention and address them

  • Found a charity to roll out valid diagnostics

  • Make EA spaces safer[19]

  • Follow me for tweets about (Long) COVID on Twitter[20]

Acknowledgements

Thanks to Justis Mills, the team of the organisation I’m working with, and especially Anne Ore for feedback on earlier versions of this document.

Footnotes

  1. ^

    I’m excluding China in this extrapolation due to much fewer acute COVID infections there.

  2. ^

    Unfortunately, none of these studies included the ME/​CFS hallmark feature of Post-Exertional Malaise (disproportionate exhaustion/​symptom flares after exertion), nor a diagnosis of orthostatic intolerance/​POTS (difficulty tolerating upright posture).

  3. ^

    I refer to multiple USDVA studies, but there is criticism that this dataset has heavy selection bias. E.g. more severe cases are more likely to get a test for COVID, dataset is skewed male while Long Covid skews female, and they use antibodies to determine prior infection (inaccurate)

  4. ^

    Excellent presentation.

  5. ^

    It’s not clear to me how this number compares to their control group.

  6. ^

    Disability rates are higher in the working population.

  7. ^

    See tab ‘Implied Recovery Rate’. This is one reason why I believe self reports are more likely to lead to underestimates than overestimates; people seem to initially not recognise their symptoms as Long Covid, especially in the case of parents reporting on their children’s health.

  8. ^

    They are very similar to UK numbers, but were more accessible

  9. ^

    Number based on vague recall of PCR sensitivity/​specifity.

  10. ^

    There are concerns that the neuropsychological testing used in this study was inadequate to pick up the specific deficits

  11. ^

    For example, see the 1919 post-pandemic famine in Tanzania; workers were too few and too disabled to harvest the full yield.

  12. ^

    There are already hospitals in Western countries unable to take emergency cases during the BA.5 peak, let alone planned treatments: e.g. UK, and Dutch hospital closing emergency department 3 days/​week (citing sick leaves & inability to hire). In the UK, there are serious excess deaths among all age groups that are thought to be the result of delayed/​lower quality care + long-term effects of COVID.

  13. ^

    Effective antiviral therapy is often much longer (>8 weeks), uses multiple antivirals to prevent antiviral resistance, ideally includes an immunosupportive drug, and requires clinical monitoring of progress and side effects.

  14. ^

    Here’s a great talk by Amy Proal, ME/​CFS and Long Covid researcher, and one of the primary proponents of the Viral Persistence Hypothesis.

  15. ^

    The current mainstream view of autoimmunity holds that a time-limited trigger or genetic defect causes the immune system to attack host cells. Long Covid is associated with autoimmune markers. If Long Covid is a chronic infection, this lends evidence to an alternative paradigm; that autoimmunity is the result of the immune system trying and failing to eradicate an ongoing trigger, such as an infection. Recently the ‘autoimmune disease’ MS has been linked to chronic Epstein-Barr Virus infection.

  16. ^

    I’ve met plenty of post-vaccine patients online. They are never anti-vaxxers, and I believe them fully.

  17. ^

    The Atlantic has the best Long Covid coverage

  18. ^

    Some high-level research considerations here

  19. ^

    I personally like Corsi-Rosenthal Boxes: cheap DIY HEPA filters that are equal to/​more effective than commercial devices. But there are many alternatives with lower time cost.

  20. ^

    Deepti Gurdasani also has very insightful threads.

SiebeRozendal11 Aug 2022 13:52 UTC
39 points
31 commentsEA link